EGF signalling and rapamycin-mediated mTOR inhibition in glioblastoma multiforme evaluated by phospho-specific flow cytometry

Current concepts and management of glioblastoma

(2011) Matthias Preusser et al.   ANNALS OF NEUROLOGY

Cancer immunology—analysis of host and tumor factors for personalized medicine

(2011) Shuji Ogino et al.   Nature Reviews Clinical Oncology

Molecular pathology in adult high-grade gliomas: from molecular diagnostics to target therapies

(2011) K. Masui et al.   NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY

mTOR signaling in glioblastoma: lessons learned from bench to bedside

(2010) D. Akhavan et al.   NEURO-ONCOLOGY

EGFR Signaling and Drug Discovery

(2010) Georg Lurje et al.   ONCOLOGY

Glioblastoma multiforme: a review of therapeutic targets

(2009) Okezie O Kanu et al.   EXPERT OPINION ON THERAPEUTIC TARGETS

Primary glioblastomas with and without EGFR amplification: Relationship to genetic alterations and clinicopathological features

(2009) Rafael Benito et al.   NEUROPATHOLOGY

The Pharmacology of mTOR Inhibition

(2009) D. A. Guertin et al.   Science Signaling

PTEN and the PI3-Kinase Pathway in Cancer

(2008) Nader Chalhoub et al.   Annual Review of Pathology-Mechanisms of Disease

A pilot study of everolimus and gefitinib in the treatment of recurrent glioblastoma (GBM)

(2008) Teri N. Kreisl et al.   JOURNAL OF NEURO-ONCOLOGY

Antitumor Activity of Rapamycin in a Phase I Trial for Patients with Recurrent PTEN-Deficient Glioblastoma

(2008) Tim F Cloughesy et al.   PLOS MEDICINE